{"nctId":"NCT03740048","briefTitle":"A Pilot Trial of Twice-weekly Versus Thrice-weekly Hemodialysis in Patients With Incident End-stage Kidney Disease","startDateStruct":{"date":"2019-06-19","type":"ACTUAL"},"conditions":["End Stage Renal Failure on Dialysis"],"count":51,"armGroups":[{"label":"Hemodialysis and Pharmacologic Therapy","type":"EXPERIMENTAL","interventionNames":["Other: Hemodialysis","Drug: Patiromer Oral Product"]},{"label":"Conventional Hemodialysis Regimen","type":"ACTIVE_COMPARATOR","interventionNames":["Other: Hemodialysis"]}],"interventions":[{"name":"Hemodialysis","otherNames":[]},{"name":"Patiromer Oral Product","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age ≥18 years\n* Incident ESKD from CKD progression (including a failing renal transplant)\n* Are deemed to require dialysis initiation by the treating nephrologist\n* Have elected HD for renal replacement therapy (RRT)\n\nExclusion Criteria:\n\n* Have urine output \\<500ml per day\n* Have ESKD as a result of severe acute kidney injury (AKI) (stage 3 AKI defined by Acute Kidney Injury Network \\[AKIN\\]) criteria)\n* Abrupt decline in kidney function preceding HD therapy initiation (i.e., if eGFR was ≥30 mL/min/1.73 m2 3 months prior to the initiation of dialysis therapy)\n* Are scheduled to undergo transplantation from a live donor within the next 6 months\n* Have an active diagnosis of hepatorenal syndrome\n* Have a significant malignancy that is likely to impact survival\n* Have a medical condition that would jeopardize the safety of the subject.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Patients' Adherence to Study Protocol","description":"≥95% of participants randomized in the intervention group will adhere to the HD regimen. All participants who completed 6 and 12 months of follow-up completed interdialytic timed urine collections - Patient adherence to the study protocol was assessed by the number of participants randomized to each intervention who adhered to the study protocol and at 6 months and at 12 months","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"24-hour Urine Volume","description":"Residual renal clearance was calculated based on 24-hour urine collection performed at baseline at enrollment; and interdialytic urine collection performed at baseline, 6 Weeks, 12 Weeks and 24 Weeks","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"914","spread":null},{"groupId":"OG001","value":"1424","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"504","spread":null},{"groupId":"OG001","value":"553","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"479","spread":null},{"groupId":"OG001","value":"484","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"862","spread":null},{"groupId":"OG001","value":"876","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Residual Kidney Function - Urea Clearance","description":"Residual renal clearance was calculated based on 24-hour urine collection performed at baseline at enrollment; and interdialytic urine collection performed during weeks 6, 12, and 24.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":null},{"groupId":"OG001","value":"4.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null},{"groupId":"OG001","value":"2.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null},{"groupId":"OG001","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null},{"groupId":"OG001","value":"2.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Residual Kidney Function - Creatinine Clearance","description":"Residual renal clearance was calculated based on 24-hour urine collection performed at baseline at enrollment; and interdialytic urine collection performed during weeks 6, 12, and 24.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.4","spread":null},{"groupId":"OG001","value":"10.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":null},{"groupId":"OG001","value":"6.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":null},{"groupId":"OG001","value":"5.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":null},{"groupId":"OG001","value":"5.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":22},"commonTop":[]}}}